Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Histologically or cytologically confirmed squamous cell carcinoma or adenocarcinoma of the esophagus. Stage T2-T3, N any, M0 (no evidence of disseminated cancer except regional involvement which may be designated as M1a). No evidence of metastatic disease~2. Medically able to tolerate major abdominal and/or thoracic surgery~3. Able to undergo EUS procedure and pass EUS probe through esophageal lumen~4. Able to receive concurrent systemic chemotherapy (cisplatin and 5-FU) and RT~5. Clinical management plan includes esophagectomy after completion of two courses of chemoradiation therapy~6. Karnofsky Performance Status of ≥ 60~7. Minimum life expectancy of 4 months~8. Hematologic function~   * Absolute neutrophil count (ANC) ≥ 1500/mm3~  * Platelet count ≥ 100,000/mm3~  * Hemoglobin ≥ 9 g/dL~9. Hepatic function:~   * Total bilirubin \< 1.5 X upper limit of normal (ULN)~  * AST and ALT \< 3 X ULN~  * Albumin ≥ 3.0 g/dL or ≥ 2.0 g/dL if the lower level is considered by the investigator to be due to nutritional depletion~10. Serum creatinine \< 1.5 mg/dL and/or creatinine clearance ≥ 65 mL/min~11. ≥ 18 years old~12. If female, must be non-pregnant, nonlactating, of non-childbearing potential, or using adequate birth control~13. Capable of understanding and agreeing to fulfill the requirements of the protocol~14. Sign the IRB/EC approved consent form~Exclusion Criteria:~1. History of anaphylaxis to planned CT contrast agent~2. Prior esophageal stent insertion, laser, or photodynamic therapy~3. Prior chest RT or major esophageal surgery~4. Any prior receipt of cytotoxic chemotherapeutic agents~5. Prior receipt of other cancer treatments (ie, Chelation therapy), vaccines, or biological response modifiers/growth factors (ie, GM-CSF, IL-2) within the past 4 weeks.~6. Prior malignancy unless disease free for ≥ 3 years. Note: basal cell/squamous carcinoma of the skin, in situ cervical or breast carcinoma, or superficial transitional cell bladder carcinoma will be allowed. Subjects with a history of low risk prostatic carcinoma (ie, clinical stage 1 or 2a, Gleason score \< or = 6 and PSA \<10 ng/mL at diagnosis) will be allowed~7. Significant currently active systemic diseases including uncontrolled diabetes, severe heart disease (New York Heart Association Class III or IV), uncontrolled hypertension, myocardial infarction within 3 months, severe bronchial obstruction, uncontrolled seizure disorder, or peripheral neuropathy greater than CTCAE grade 1~8. Allergies to any of the active or inactive components of OncoGel (ie, allergies to degradable PLGA \[poly(lactide-co-glycolide) sutures\])~9. Receipt of an investigational drug or device within 30 days prior to signing informed consent~10. Any medical condition or other circumstance that, in the Investigator's opinion, would prevent completion of the study, interfere with analysis of the study results, or potentially adversely affect subject safety~11. Known esophageal varices

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): OncoGel, radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.
- Group 2 (Type: ACTIVE_COMPARATOR): Radiation therapy and systemic chemotherapy (cisplatin plus 5-FU) prior to surgical resection.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy